FCHS First Choice Healthcare Solutions, Inc.
Services-Medical Laboratories · OTC · SEC CIK 1416876 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-552.3%
TTM EPS YoY-518.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-729.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets657.7%
Debt / equity—
Current ratio0.01x
Interest coverage-0.14x
Cash quality & payout
Operating cash flow / net income0.12x
Accruals ratio-645.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | $1,664 | $230 | $1,423 | $4,033 | — |
| SG&A expense | $519,887 | $439,176 | $629,082 | $497,130 | $210,528 | $432,259 | $476,828 | -$168,343 |
| Operating income | -$690,372 | -$535,978 | -$731,332 | -$890,999 | -$621,161 | -$574,414 | -$584,456 | $136,483 |
| Interest expense | $9.98M | $6.68M | $704,389 | $2.57M | $841,724 | $515,534 | $785,896 | $883,716 |
| Pretax income | -$10.68M | -$7.01M | -$1.44M | -$3.46M | -$1.46M | -$639,436 | -$1.40M | $148,718 |
| Net income | -$10.68M | -$7.01M | -$1.44M | -$3.46M | -$1.46M | -$639,436 | -$1.40M | $36,768 |
| EBITDA | -$687,466 | -$533,071 | -$728,426 | -$887,308 | -$617,058 | -$570,311 | -$578,826 | $145,087 |
| EPS (basic) | -0.32 | -0.21 | -0.04 | — | -0.04 | -0.02 | -0.04 | — |
| EPS (diluted) | -0.32 | -0.21 | -0.04 | — | -0.04 | -0.02 | -0.04 | — |
| Weighted avg. shares (diluted) | 32.96M | 32.96M | 32.96M | — | 32.96M | 32.96M | 32.96M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $135,212 | $6,842 | $3,859 | $5,896 | $2,430 | $6,454 | $29,645 | $19,915 |
| Receivables | $37,611 | $403 | $40,575 | $717 | $1,173 | $9,459 | $40,287 | $72,270 |
| Current assets | $172,823 | $7,245 | $44,434 | $6,613 | $3,603 | $15,913 | $69,932 | $92,185 |
| PP&E, net | $59,118 | $141,148 | $144,055 | $146,961 | $150,653 | $154,756 | $179,646 | $222,816 |
| Total assets | $2.08M | $576,493 | $4.05M | $4.05M | $4.11M | $4.22M | $4.40M | $4.51M |
| Current liabilities | $13.68M | $10.08M | $42.23M | $40.67M | $37.16M | $35.69M | $34.64M | $33.27M |
| Total liabilities | $13.68M | $10.08M | $45.04M | $43.58M | $40.16M | $38.78M | $38.29M | $36.98M |
| Shareholders' equity | -$11.60M | -$9.51M | -$40.99M | -$39.53M | -$36.04M | -$34.56M | -$33.89M | -$32.47M |
| Shares outstanding | 32.96M | 32.96M | 32.96M | 32.96M | 32.96M | 32.96M | 32.96M | 32.96M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.42M | $142,984 | -$327,038 | $3,466 | -$163,570 | -$96,884 | -$292,031 | -$2.39M |
| Investing cash flow | — | — | — | $0 | $0 | $0 | $10,000 | $1.65M |
| Financing cash flow | $2.55M | -$140,000 | $325,000 | $0 | $159,546 | $73,694 | $291,760 | $764,445 |
| Depreciation & amortization | $2,906 | $2,907 | $2,906 | $3,691 | $4,103 | $4,103 | $5,630 | $8,604 |
Free plan shows the latest 8 periods; Pro shows all 50 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.